Annexon reported promising Phase 3 results for tanruprubart in Guillain-Barré syndrome, a potential advance in a rare neurological disease with limited treatmen

Annexon reported promising Phase 3 results for tanruprubart in Guillain-Barré syndrome, a potential advance in a rare neurological disease with limited treatment options. The therapy targets the underlying disease mechanism; further updates are pending.